A- A A+

Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs. 

Krawczyk N, Maniates H, Hulsey E, Smith JS, DiDomenico E, Stuart EA, Saloner B, Bandara S. 

J Addict Med. 2022 Nov-Dec 01;16(6):645-652. doi: 10.1097/ADM.0000000000000981. PMID: 35165225; PMCID: PMC9653109.


Triple Threat: Response to the Crises of COVID-19, Homelessness, and Opioid Use Disorder With a Novel Approach to Buprenorphine Delivery: A Case Series. 

Samuel L, Caygill-Walsh R, Suen LW, Mohebbi S, Geier M. 

J Addict Med. 2022 Nov-Dec 01;16(6):733-735. doi: 10.1097/ADM.0000000000000989. PMID: 35245914; PMCID: PMC9653064.


Impacts of the New York State COVID-19 Disaster Emergency Orders on prescription dispensing for opioids and medication for opioid use disorder. 

Suri A, Feaster DJ, Balise RR, Quinn J, Nunes EV, Gilbert L, El-Bassel N, Rundle AG.

Addiction. 2022 Nov 18. doi: 10.1111/add.16087. Epub ahead of print. PMID: 36398540.



HIV Exposure Prophylaxis Delivery in a Low-barrier Substance Use Disorder Bridge Clinic during a Local HIV Outbreak at the Onset of the COVID-19 Pandemic. 

Braun HM, Walter C, Farrell N, Biello KB, Taylor JL. 

J Addict Med. 2022 Nov-Dec 01;16(6):678-683. doi: 10.1097/ADM.0000000000000991. PMID: 36383918; PMCID: PMC9653062.


Impact of COVID-19 & Response Measures on HIV-HCV Prevention Services and Social Determinants in People Who Inject Drugs in 13 Sites with Recent HIV Outbreaks in Europe, North America and Israel. 

Wiessing L, Sypsa V, Abagiu AO, Arble A, Berndt N, Bosch A, Buskin S, Chemtob D, Combs B, Conyngham C, Feelemyer J, Fitzgerald M, Goldberg D, Hatzakis A, Patrascu RE, Keenan E, Khan I, Konrad S, Leahy J, McAuley A, Menza T, Merrick S, Metcalfe R, Rademaker T, Revivo S, Rosca P, Seguin-Devaux C, Skinner S, Smith C, Tinsley J, Wilberg M, Des Jarlais D. 

AIDS Behav. 2022 Nov 11:1–14. doi: 10.1007/s10461-022-03851-x. Epub ahead of print. PMID: 36367613; PMCID: PMC9651099.


Disruptions to U.S. local public health's role in population-based substance use prevention and response during COVID-19. 

Hall K, Higgins F, Beach KF, Diriba K, Sladky M, McCall TC. 

Subst Abuse Treat Prev Policy. 2022 Nov 7;17(1):73. doi: 10.1186/s13011-022-00499-7. PMID: 36345019; PMCID: PMC9640804.


Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID. 

Meyerson BE, Bentele KG, Russell DM, Brady BR, Downer M, Garcia RC, Garnett I, Lutz R, Mahoney A, Samorano S, Arredondo C, Andres HJ, Coles H, Granillo B. 

PLoS One. 2022 Oct 25;17(10):e0274094. doi: 10.1371/journal.pone.0274094. PMID: 36282806; PMCID: PMC9595554.


Innovations, adaptations, and accelerations in the delivery of HIV services during COVID-19

Murphy, Eamonn et al.

The Lancet HIV, Volume 0, Issue 0 


Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic. 

Frost MC, Zhang L, Kim HM, Lin LA. 

JAMA Netw Open. 2022 Oct 3;5(10):e2236298. doi: 10.1001/jamanetworkopen.2022.36298. PMID: 36223118; PMCID: PMC9557869.


Drugs and alcohol Use patterns among those seeking care in urban rehabilitation centres before and during early months of COVID-19 in Uganda. 

Tumwesigye NM, Ocama P, Basangwa D, Matovu F, Abbo C, Wamala T, Biribawa C, Namanda C, Blessing J, Twesigomwe R. 

Afr Health Sci. 2022 Aug;22(Spec Issue):93-107. doi: 10.4314/ahs.v22i2.15S. PMID: 36321113; PMCID: PMC9590330.


Sustainment of Contingency Management within Opioid Treatment Programs: COVID-Related Barriers and Innovative Workflow Adaptations. 

Becker SJ, Bowen CA, Reed EN, Lang S, Correia N, Yermash J, Yap KR, Rash CJ, Garner BR. 

Drug Alcohol Depend Rep. 2021 Dec;1:100003. doi: 10.1016/j.dadr.2021.100003. Epub 2021 Nov 22. PMID: 36277301; PMCID: PMC9585956.


Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England. 

Aldabergenov D, Reynolds L, Scott J, Kelleher MJ, Strang J, Copeland CS, Kalk NJ. 

Int J Drug Policy. 2022 Oct 4;110:103877. doi: 10.1016/j.drugpo.2022.103877. Epub ahead of print. PMID: 36265326; PMCID: PMC9531664.


Managing acute opioid withdrawal with tramadol during COVID-19 lockdown in a peri-urban setting. 

Bhoora U, Gloeck NR, Scheibe A. 

Afr J Prim Health Care Fam Med. 2022 Sep 28;14(1):e1-e9. doi: 10.4102/phcfm.v14i1.3386. PMID: 36226932; PMCID: PMC9557935.


A pilot study comparing in-person and remote outpatient substance use treatment services on quality-of-life outcomes. 

Tomlinson MF, Thomas MP, Goldman B, Bourdon J, Vadhan NP. 

Drug Alcohol Depend Rep. 2022 Dec;5:100108. doi: 10.1016/j.dadr.2022.100108. Epub 2022 Oct 7. PMID: 36247931; PMCID: PMC9536869.


Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers. 

Sung ML, Black AC, Blevins D, Henry BF, Cates-Wessel K, Dawes MA, Drexler K, Hagle H, Molfenter T, Levin FR, Becker WC, Edelman EJ. 

J Addict Med. 2022 Sep-Oct 01;16(5):505-513. doi: 10.1097/ADM.0000000000000948. Epub 2022 Jan 11. PMID: 35020698; PMCID: PMC9271533.


Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic. 

Hallgren KA, Darnton J, Soth S, Blalock KL, Michaels A, Grekin P, Saxon AJ, Woolworth S, Tsui JI. 

J Subst Abuse Treat. 2022 Oct 4;143:108896. doi: 10.1016/j.jsat.2022.108896. Epub ahead of print. PMID: 36215911; PMCID: PMC9531364.


Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic. 

Tilhou AS, Dague L, Saloner B, Beemon D, Burns M. 

JAMA Health Forum. 2022 Mar 11;3(3):e220093. doi: 10.1001/jamahealthforum.2022.0093. PMID: 35977284; PMCID: PMC8917419.


Effects of Unemployment on Opioid Use Treatment Trajectories: Impact of the COVID-19 Pandemic. 

Mumba MN, Davis L, Smith NL, Evans T, Castillo R. 

J Addict Nurs. 2022 Jul-Sep 01;33(3):168-171. doi: 10.1097/JAN.0000000000000480. PMID: 36041159; PMCID: PMC9435955.


Thirty-day Treatment Continuation After Audio-only Buprenorphine Telehealth Initiation. 

Wunsch C, Wightman R, Pratty C, Jacka B, Hallowell BD, Clark S, Davis CS, Samuels EA. 

J Addict Med. 2022 Sep 14. doi: 10.1097/ADM.0000000000001077. Epub ahead of print. PMID: 36102540.



Physician response to COVID-19-driven telehealth flexibility for opioid use disorder. 

Beetham T, Fiellin DA, Busch SH. 

Am J Manag Care. 2022 Sep;28(9):456-463. doi: 10.37765/ajmc.2022.89221. PMID: 36121359.


Impacts of the COVID-19 Pandemic on a Rural Opioid Support Services Program. 

Walters JE, Jones AE, Brown AR, Wallis D. 

Int J Environ Res Public Health. 2022 Sep 6;19(18):11164. doi: 10.3390/ijerph191811164. PMID: 36141436; PMCID: PMC9517684.


People engaged in opioid agonist treatment as a counterpublic during the COVID-19 pandemic in Australia: A qualitative study. 

Conway, A, Treloar, C, Crawford, S, Grebely, J, Marshall, AD. 

Drug Alcohol Rev. 2022. doi.org/10.1111/dar.13531


Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. 

Jones CM, Shoff C, Hodges K, et al. 

JAMA Psychiatry. Published online August 31, 2022. doi:10.1001/jamapsychiatry.2022.2284


USA. Methadone, the Early Pandemic and the Terror of a Poppyseed Positive

I was going to the methadone clinic weekly when the pandemic began. That was the maximum at the place I was transferred to just before Christmas 2019, after my clinic of 10 years closed. Many people have to attend clinics daily. But for a decade, I had been going only every two weeks, so weekly was hard for me. (Filter, USA, 18.08.2022)


COVID-19 and the opportunity for gender-responsive virtual and remote substance use treatment and harm reduction services. 

Perri M, Schmidt RA, Guta A, Kaminski N, Rudzinski K, Strike C. 

Int J Drug Policy. 2022 Aug 8;108:103815. doi: 10.1016/j.drugpo.2022.103815. Epub ahead of print. PMID: 35969920; PMCID: PMC9359504.


Women-Reported Barriers and Facilitators of Continued Engagement with Medications for Opioid Use Disorder. 

Fiddian-Green A, Gubrium A, Harrington C, Evans EA. 

Int J Environ Res Public Health. 2022 Jul 30;19(15):9346. doi: 10.3390/ijerph19159346. PMID: 35954700; PMCID: PMC9368271.


Opioid agonist treatment take-home doses ('carries'): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA? 

Russell C, Lange S, Kouyoumdjian F, Butler A, Ali F. 

Harm Reduct J. 2022 Aug 10;19(1):89. doi: 10.1186/s12954-022-00671-z. PMID: 35948961; PMCID: PMC9363267.


Factors Associated With Increased Opioid Use During the COVID-19 Pandemic: A Prospective Study of Patients Enrolled in Opioid Agonist Treatment. 

Rosic T, Naji L, Sanger N, Marsh DC, Worster A, Thabane L, Samaan Z. 

J Addict Med. 2022 Jul-Aug 01;16(4):e257-e264. doi: 10.1097/ADM.0000000000000939. Epub 2021 Nov 16. PMID: 34789682; PMCID: PMC9365071.


In-Person Versus Telehealth Setting for the Delivery of Substance Use Disorder Treatment: Ecologically Valid Comparison Study. 

Ngo QM, Braughton JE, Gliske K, Waller LA, Sitar S, Kretman DN, Cooper HLF, Welsh JW. 

JMIR Form Res. 2022 Apr 4;6(4):e34408. doi: 10.2196/34408. PMID: 35377318.


WHO. Good practices in managing infectious diseases in prison settings: a snapshot of responses to COVID-19 implemented around the globe between May and September 2020 (2022)

This report captures various health-related policies and practices that were implemented inside prisons and other places of detention during the COVID-19 pandemic. It is intended as a resource for policy-makers, prison managers and health-in-prisons practitioners, highlighting the preparedness, responsiveness, risk assessment, risk mitigation and case management of COVID-19 inside prisons. The report presents good practices from countries and regions, selected according to specific criteria, in enhancement of health-care practices in prisons. It is structurally based on, and thematically complementary to, Preparedness, prevention and control of COVID-19 in prisons and other places of detention: interim guidance, developed by the WHO Regional Office for Europe and issued in March 2020 (‎revised February 2021)‎. The robust methodology used to capture good practices and their selection within a fixed submission window within 2020 mean that some developments in response measures in prisons could not be covered in this report. (WHO, 2022)